NasdaqGS:KNSABiotechs
Kiniksa Pharmaceuticals (KNSA) Profit Surge Challenges Valuation Caution as Growth Outpaces Peers
Kiniksa Pharmaceuticals International (KNSA) turned profitable in the last year, with net profit margins improving and earnings growing at a 40.7% annual rate over the past five years. Looking ahead, analysts expect earnings to climb another 33.3% per year on average for the next three years. This is notably faster than both the US market and the company’s own revenue forecast, which is set at 16.7% annual growth. These trends position the company as one with robust ongoing momentum and...